# 41st Annual J.P. Morgan Healthcare Conference

Dr. Helen Torley, President and CEO

*January 10, 2023*

# Forward Looking Statements

In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including the Company's financial outlook for 2022 and 2023) and expectations for profitability, revenue (including expectations for future royalties and product sales), cash flow, operating income, and earnings-per-share, and the Company's plans to repurchase shares under its share repurchase program and to potentially expand the Company's platform through acquisitions. Forward-looking statements regarding the Company's ENHANZE® drug delivery technology include the possible benefits and attributes of ENHANZE® including its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and facilitating more rapid delivery and administration of larger volumes of injectablemedications through subcutaneous delivery and potential to decrease treatment burden and decrease healthcare costs. Forward-looking statements regarding the Company's ENHANZE® business may include potential growth driven by our partners' development and commercialization efforts (including anticipated new clinical trialstarts, study readouts, ENHANZE® product approvals and launches and the timing related to these events), projections for future sales revenue of our collaborators' products, potential new ENHANZE® collaborations, collaborative targets and indications for ENHANZE® products, co-formulation intellectual property and the Company's plans to develop a large volume auto-injector and new formulations of its API for longer intellectual property protection. These forward-looking statements are typically, but not always, identified through use of the words "believe," "enable,""may," "will,""could," "intends," "estimate,""anticipate,""plan," "predict,""probable," "potential,""possible," "should," "continue," and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected levels of revenues (including royalty and milestone revenue received from our collaboration partners and product sales), expenditures and costs, unexpected delays in the execution of the Company's share repurchase program or planned platform expansion, unexpected results or delays in the growth of the Company's ENHANZE® business (including as a result of unexpected conversion rates), obtaining new co-formulation intellectual property, or in the development, regulatory review or commercialization of new formulations of the Company's API or its partners' ENHANZE® products, unexpected delays in the Company's plans to develop a large volume auto-injector, including any potential delays caused by the current COVID-19 global pandemic, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.

**Non-GAAP Financial Measures:**
In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), these materials contain certain non-GAAP financial measures. The Company reports EBITDA and non-GAAP diluted earnings per share and expectations of those measures in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company uses Non-GAAP financial information in assessing what it believes is a meaningful and comparable set of financial performance measures to evaluate operating trends, as well as in establishing portions of our performance-based incentive compensation programs. The Company does not provide reconciliations of forward-looking adjusted measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for changes in contingent liabilities, share-based compensation expense and the effects of any discrete income tax items.

Note: This presentation contains product names, trademarks and registered trademarks that are property of their respective owners.

# **What We Do:** License Drug Delivery Platforms to Partners, and Commercialize Specialty Products

## Drug Delivery Platform Technologies

### ENHANZE®

**Commercially-Validated**

**Sub-Cutaneous Delivery**

- 5 approved partnered products
- Approved in 100+ countries
- >600,000 patients have received ENHANZE®- enabled treatments

### Auto-Injectors

Commercialized & development stage devices for broad application


## Commercial Portfolio

### Specialty Products

Hylenex® recombinant (hyaluronidase human injection)

XYOSTED® (testosterone enanthate) injection CIII

TLANDO® (testosterone undecanoate) CIII

# 2023 Select Financial Guidance Highlights

| | 2022 | 2023 | |
|---|---|---|---|
| **Total Revenue** | $655M - $685M | **$815M - $845M** | >20% YoY growth |
| **Royalty Revenue** | $350M - $360M | **$445M - $455M** | >20% YoY growth |
| **EBITDA** | $310M - $335M | **$415M - $440M** | >30% YoY growth<br>Excludes impact of amortization costs in 2023 related to the Antares acquisition |

# **Halozyme** Investment Highlights

**Profitable, high-growth biopharma company with diversified revenue streams**

**New Potential Royalty Revenue Opportunity**

- **2 Potential ENHANZE® SC Approvals in 2023**
- **2 Additional Potential ENHANZE® SC Approvals by 2025**

**New Opportunity 2023: ENHANZE® plus large volume auto-injectors (LVAI)**

# Halozyme: Delivering Strong & Durable Growth

01 **Differentiated Growth Platforms**

02 >$1B ENHANZE® Opportunity

03 Specialty Product Opportunity

04 Durable Revenue and Financial Strength

# The World Needs More Subcutaneous Large and Small Molecule Drug Delivery

## Potential benefits for **Patient and Caregivers**

- **Decreased treatment burden**
  - Hours to minutes[2]
- **Improved patient experience**
  - Prefer SC vs. IV[1]
  - Optionality[5]
- **Lower infusion related reactions IRRs**[3,4,6]

## Potential benefits for **Healthcare System (providers, nurses, pharmacists, payers)**

- **Potential to decrease healthcare costs:**
  - Less use of more costly hospital/ infusion centers[7]
  - Greater patient throughput for clinics
  - Decrease HCP time in administration[7]
  - Decreased drug wastage[8] (fixed vs. weight-based dosing)

Sources: [1] Piv ot X, Gligorov J, Müller V, et al. "Patients' Preference for SC v s. IV", Annals of Oncology, 2014; 3:4. [2] Stephen P. Knowles, Marie A. Printz, David W. Kang, Michael J. LaBarre & Renee P. Tannenbaum (2021): Safety of recombinant human hyaluronidase PH20 for subcutaneous drug d eliv ery, Expert Opinion on Drug Deliv ery, DOI: 10.1080/17425247.2021.1981286. [3] Chari A, Nahi H, Mateos M-V, et al. Presented at: ASH Annual Meeting; Dec 9-12, 2017; Atlanta, GA. [3] Lancet Haematol. "Subcutaneous v ersus intrav enous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicen ter, open-label, non-inferiority, randomised, phase 3 trial"; 2020. [4] Wasserman RL, Melamed I, Stein M, et al. Meeting of the ACAAI; Nov 3-8, 2011; Boston, MA. [5] Rummel M, Kim TM, Av ersa F, et al. "Preference for subcutaneous or intrav enous administration", Annals of Oncology 28 , no 4 (2016): 836,838. [6] Chari A, Nahi H, Mateos M-V, et al. Presented at: ASH Annual Meeting; Dec 9-12, 2017; Atlanta, GA. [7] Sanchez, ClinicoEconomics and Outcomes Research: 2019: 695. [8] Hendrikx, "Fixed Dosing of Monocolonic Antibodies in Oncology" The Onoclogist 2017; 22; 1212-122.

# **ENHANZE®**: Patented, De-risked, Commercial Platform Technology Enabling Rapid, Large Volume Subcutaneous Delivery of IV Drugs



**What it does:** ENHANZE® creates temporary space for SC fluid dispersion which returns to normal; reduces backpressure

**ENHANZE®**

Uniquely enables rapid SC delivery
- 5-15mL over 2-5 minutes
- 300-600mL at 5 mL/min

Decreased injection site swelling and induration

Aids absorption leading to increased bioavailability versus subcutaneous without ENHANZE®[1]

Potential for decreased systemic infusion related reactions

[1] Morcos International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 7/2013 (537-548)

# Established Drug Delivery Leadership:
## 5 Globally-Approved Partner Products, Robust and Diverse Pipeline

**5**
**Approved Products**

**100+**
**Countries**

**>600,000**
**Patients have received ENHANZE®–enabled SC products**

**2** Partner Products in Regulatory Review

**4** Partner Products in/soon to start Phase 3

**8** Partner Products in/ completed Phase 1

# Multiple Target Opportunities Open for ENHANZE®

| Therapeutic Area | Targets Taken Exclusively | Available IV High Volume Targets* |
|---|---|---|
| Oncology | 9 | 23 |
| CNS | 1 | 10 |
| Hematologic | 1 | 11 |
| Autoimmune Diseases | 4 | 8 |
| Cardiovascular/Metabolic | 0 | 6 |
| Infectious Disease | 5 | 5 |
| **TOTAL** | **20** | **63** |

In

Sources: Evaluate Ltd and Citeline Pharmaprojects

# **Halozyme** Differentiated Proprietary and Partner Small Volume Auto-Injectors (SVAI),Commercially Available and Widely Licensable


## QuickShot™ and BigShot™ Auto Injectors

1 mL and 2.25 mL
SC or IM

XYOSTED® (testosterone enanthate) injection

Pfizer

*Undisclosed*

idorsia

*Selatogrel*


## VIBEX™ Auto Injectors

1 mL
SC or IM

teva

*Generic EpiPen*

teva

*Generic Imitrex*

Otrexup® (methotrexate) injection
*for subcutaneous use*

*Assertio Holdings*


## VAI™ Auto Injectors

2.25 mL
SC or IM

***ATRS-1902***
***(development stage)***


## Pen Injector Systems

1.5 mL and 3.0 mL
multi-dose, disposable

teva

*Generic Forteo*

# 8M units in 2022

Note: All product names, trademarks and registered trademarks are property of their respective owners.

# **NEW in 2023:** ENHANZE® Plus Auto-Injector Facilitates >5mL to 10mL Auto-Injector

ENHANZE® + **Halozyme Auto-Injector Technology and Know How** ▶ **Large Volume >5mL Auto-Injector**

- Creates space for fluid dispersion
- Reduces backpressure
- Reduces leakage to deliver planned dose

Customizable technology to meet partner needs

**2023**: Complete clinical feasibility testing

# **Halozyme:** Delivering Strong & Durable Growth

01 Differentiated Growth Platforms

02 **>$1B ENHANZE® Opportunity**

03 Specialty Product Opportunity

04 Durable Revenue and Financial Strength

# ENHANZE®: Durable Revenue Potential and Strong Future Growth Opportunities

| Waves 1 & 2 | Wave 3 | Wave 4 | Wave 5 |
|---|---|---|---|
| 5 Globally-Approved Products | 4 Product Candidates | 10 Product Candidates | |
| DARZALEX Faspro® (daratumumab and hyaluronidase-fihj) Injection for subcutaneous use \| 1,800mg/30,000units<br>PHESGO® pertuzumab/trastuzumab/hyaluronidase-zzxf SUBCUTANEOUS INJECTION<br>HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]<br>Herceptin® trastuzumab<br>MabThera SC Rituximab Subkutant | Launch Potential 2023-2025<br>Efgartigimod SC*<br>Atezolizumab SC**<br>Nivolumab SC<br>Ocrelizumab SC | Launch Potential 2025-2027<br>8 in/completed Phase 1<br>2 in/soon to start Phase 3 | Launch Potential 2027+<br>New nominations from current and new partners |
| **Revenue drivers 2021+** | **Revenue drivers 2023-2025** | **Revenue drivers 2025-2027** | **Revenue drivers 2027+** |

2021-2023 milestone revenue now projected to be $330-360M[1]

2022-2024 milestone revenue projection unchanged at $450-$500M[1]

* Submitted for regulatory approval ** Submission to regulatory authorities ongoing
[1] Includes development, commercial and upfront milestones and other collaboration revenue

# ENHANZE®: A Royalty Growth Story

## Projected Royalty Revenue Potential




2027 projection based on approved products and assumes global approval and launches of approximately 20 additional products in multiple indications. Includes projections for subcutaneous versions for targets not currently approved or commercially available. Assumes approved and under review co-formulation patents, Innovator revenues based on Bloomberg or Evaluate Ltd analyst-based estimates when available. Conversion rates based on Halozyme internal projections. Royalty revenue projections includes targets selected and not yet disclosed. Projected royalty revenue is not risk-adjusted. Royalty rate mid-single digit range across all products

# **Total Royalties**: Projecting Record Royalty Revenue in 2023

## Projecting >20% growth in 2023




*Includes auto-injector royalties

# Wave 2: Launch Growth Drivers

## DARZALEX SC/FASPRO® Share and Revenue Growth Continues

**Total DARZALEX® Sales IV+SC ($B) [1]**




**DARZALEX FASPRO® Share of Total US DARZALEX® Sales[2]**




[1] Analysts' consensus from Evaluate Ltd October 2022
[2] 2022 Symphony Health (subscription data presented with permission)

# Wave 2: Launch Growth Drivers

## Phesgo® Share and Revenue Growth Continues

### Total Perjeta® Sales ($B) [1]




### Phesgo®[2]

**Phesgo's strong global launch continues**

Global Phesgo conversion rate*




- Phesgo conversion rate at 30% in early launch countries
- Phesgo significantly cuts healthcare costs and resource use
- P+H in eBC (APHINITY): 8-year follow up data presented at ESMO Virtual Plenary showing a 28% reduction in the risk of recurrence or death for high risk, lymph-node positive patients
- Ph III (heredERA) Phesgo + giredestrant in 1L HER2+/HR+ mBC initiated

[1] Analysts' consensus from Evaluate Ltd October 2022
[2] Roche's Third Quarter 2022 Results

*Phesgo® conversion rate is based on volumes (vials) and includes all launch countries after the 2nd quarter after the launch (25 countries).

# **Wave 3:** Four Potential Launches 2023-2025

| Products | | | Disease Areas | Milestones | Potential Launch[1] |
|---|---|---|---|---|---|
| argenx | Efgartigimod | **IV APPROVED (gMG)** | gMyasthenia Gravis<br><br>Other Indications | Completed SC with ENHANZE® BLA submission in September 2022<br><br>Additional SC with ENHANZE® data readouts projected in 2023 | **2023** for gMyasthenia Gravis |
| Roche | Atezolizumab | **IV APPROVED** | Phase 3 in Non-Small Cell Lung Cancer[2] | Submission to regulatory authorities ongoing | **2023** |
| Roche | Ocrelizumab | **IV APPROVED** | Multiple Sclerosis | Phase 3 data readout projected in 2023 | **2024** |
| Bristol Myers Squibb | Nivolumab | **IV APPROVED** | Phase 3 studies in:<br>Clear Cell Renal Cell Carcinoma<br>Melanoma | Phase 3 ongoing | **TBD** |

[1] Halozyme assessment based on company statements on pivotal data availability. Assumes 6 months for BLA submission filing and 10-month FDA review.
[2] Roche pursuing label for multiple indications

# **Wave 3:** Developing SC Versions of Diverse, Blockbuster Products

## Parent Products Projected at >$30B in 2028[1]

### Efgartigimod

First-in-class anti-FcRn

Approved as IV for Generalized Myasthenia Gravis

Potential to address unmet need in ~15 indications

Analysts' projections: ~$4.7B in 2028[1]

### Atezolizumab

Leading anti-PDL1

Currently approved in 5 cancer types

Analysts' projections: ~$7.0B in 2028[1]

### Nivolumab

Currently approved in 10+ cancer types

Analysts' projections: ~$13.4B in 2028[1]

### Ocrelizumab

Number 1 Multiple Sclerosis treatment US and EU 5[2]

Widely studied with long term data

Analysts' projections: ~$8.2B in 2028[1]

[1] Analysts' consensus from Evaluate Ltd October 2022
[2] Roche's Third Quarter 2022 Results

# **Efgartigimod SC:** Potential to Transform Treatment Approach for Patients with Autoimmune Diseases

## Efgartigimod sales **$4.7B** in 2028, with significant ex-US sales[1]


## Extensive SC Development and Large Opportunity

| | SC | IV | SC status | WW Total Opportunity Projection 2028[1] |
|---|---|---|---|---|
| gMyasthenia Gravis | ✓ | ✓ | US PDUFA date: March 20, 2023 Submitted EMA | $2.1B |
| CIDP | ✓ | | Phase 3 SC data: Q2 2023 | $1.2B |
| ITP | ✓ | ✓ | Positive IV data Phase 3 SC data: 2H 2023 | $0.5B |
| Pemphigus | ✓ | | Phase 3 SC data: 2H 2023 | $0.3B |
| Bullous Pemphigoid | ✓ | | Phase 2/3 ongoing | $0.4B |
| Myositis | ✓ | | Phase 2/3 ongoing | |

## ENHANZE® Potential Impact

- Rapid, SC injection ~1 minute versus 60 minutes for IV
- May facilitate penetration into early disease patients

[1] Analysts' consensus and projections from Evaluate Ltd October 2022

# **Atezolizumab SC:** Potential to Reduce Treatment Burden, Help Alleviate Infusion Clinic Capacity Constraints

Total Atezolizumab sales **~$7B** in 2028, with significant ex-US sales[1]


SC Opportunity

| TECENTRIQ Monotherapy +/- Oral Therapy | TECENTRIQ IV Combination Indications |
|---|---|
| **FDA Approved Indications** | **FDA Approved Indications** |
| Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer |
| Melanoma | Hepatocellular Cancer |
| Alveolar Soft Part Sarcoma | Small Cell Lung Cancer |

ENHANZE® Potential Impact

- Submission to regulatory authorities ongoing, seeking approval across all indications
- Rapid SC injection over 7 minutes versus 30-60 mins IV
- Potential to reduce healthcare utilization and reduce cost in monotherapy and combination setting
- May be appropriate for out of hospital administration by a healthcare professional

[1] Analysts' consensus and projections from Evaluate Ltd October 2022

# **Nivolumab SC:** Potential to Reduce Treatment Burden, Help Alleviate Infusion Clinic Capacity Constraints

Total Nivolumab sales **~$13.4B** in 2028, with significant ex-US sales[1]


ENHANZE®
Potential Impact

- Phase 3 SC Opdivo monotherapy studies ongoing
  - Renal Cell Carcinoma
  - Melanoma
- Phase 3 Nivolumab and Relatlimab SC fixed combination in Melanoma study soon to start

[1] Analysts' consensus and projections from Evaluate Ltd October 2022

# **Ocrelizumab SC:** Meaningful Reduction in Administration and Observation Schedule Adds to Competitive Profile

Ocrelizumab sales **~$8.2B** in 2028, with significant ex-US sales[1]


ENHANZE®
Potential Impact

ENHANZE® could reduce administration and observation schedule to 60 mins for first 2 doses and **10 mins for all subsequent doses**[2]




- Ph III (OCARINA II) evaluating subcutaneous Q6M dosing of Ocrevus for non-inferiority vs Ocrevus IV in RMS & PPMS with data expected in 2023
- Increases potential for Ocrevus use in centers with IV capacity constraints
- Final dose monitoring requirements for SC subject to regulatory review

[1] Analysts' consensus and projections from Evaluate Ltd October 2022
[2] Roche's Third Quarter 2022 Results
RMS=relapsing multiple sclerosis; PPMS=primary progressive MS; Q6M=dosing every 6 months

# **Wave 4:** Multiple Potential Launches

**Analysts' Consensus Revenue For All Parent Products in 2028: >$60B[1]**

| ONCOLOGY | IMMUNE/ AUTOIMMUNE | HIV |
|---|---|---|
| Nivolumab+Relatlimab (BMS) **IV APPROVED** **SC soon to start Phase 3** | Teprotumumab-trbw (Horizon) **IV APPROVED** | N6LS bnAb (ViiV) |
| Amivantamab (Janssen) **IV APPROVED** **SC in Phase 3** | ARGX-117 (argenx) | Cabotegravir (ViiV) **Oral and IM APPROVED** |
| | TAK-881 (Takeda) | Rilpivirine (Janssen) **Oral APPROVED** |

**In or have completed Phase 1**

[1] Analysts' consensus for Wave 1-4 products from Evaluate Ltd. October 2022 excluding, ARGX-117 (argenx), undisclosed (Roche), undisclosed (Chugai), TAK-881 (Takeda) and N6LS(Viiv)

Table excludes Roche undisclosed target, Chugai undisclosed target, each in Phase 1

# **Halozyme:** Delivering Strong & Durable Growth

01 Differentiated Growth Platforms

02 >$1B ENHANZE® Opportunity

03 **Specialty Product Opportunity**

04 Durable Revenue and Financial Strength

# **Testosterone Replacement Therapy Portfolio:**
## Targeting to Generate >$100M XYOSTED Revenue in 2023

| FOCUS | FOCUS | OPPORTUNITY |
|---|---|---|
| XYOSTED® (testosterone enanthate) injection Ⓒ | TLANDO® (testosterone undecanoate) Ⓒ | ~8.5M TRX prescribed for testosterone replacement therapy in 2022 |
| Once-a-week dosing | 2X/daily oral administration | Growing ~5% YOY |
| Virtually painless subcutaneous injection using auto-injector technology | First oral TRT without titration requirement | Switch strategy from IM and gels |
| 21 Orange Book-listed patents extending to 2038 | | **Each 1% share gain ~$20M in net sales** |
| *Launched November 2018* | *Launched June 2022* | |

# **Halozyme:** Delivering Strong & Durable Growth

01 Differentiated Growth Platforms

02 >$1B ENHANZE® Opportunity

03 Specialty Product Opportunity

04 **Durable Revenue and Financial Strength**

# Halozyme Strategic and Capital Allocation Priorities

## Invest to Maximize Revenue Growth and Durability

- ENHANZE®
- Auto-injector innovation
- Commercial opportunity

## Continue to Return Capital to Shareholders

Second Plan: December 2021

$750M 3-year share buyback

- $350M completed through December 2022
- $150M planned in 2023 pending market conditions and other factors

## Identify Opportunities for External Growth

- Focus on integration
- Continue to evaluate opportunities to accelerate and extend revenue

# 2023: Projected Acceleration in Royalty Generating Products




* Phase 3 soon to start

# 2023 Financial Guidance Highlights

| | 2022 | 2023 | |
|---|---|---|---|
| **Total Revenue** | $655M - $685M | **$815M - $845M** | • >20% YoY growth<br>• Product Sales expected to increase due to full year Antares contribution and increasing ENHANZE API demand<br>• Includes one new deal milestones<br>• Total collaboration revenue expected to be relatively flat compared to 2022 |
| **Royalty Revenue** | $350M - $360M | **$445M - $455M** | • >20% YoY growth<br>• Continued DARZALEX® and Phesgo® uptake and full year Antares device royalty contribution |
| **EBITDA** | $310M - $335M | **$415M - $440M** | • >30% YoY growth<br>• Excludes impact of amortization costs in 2023 related to the Antares acquisition |
| **Non-GAAP Diluted EPS** | $2.10 - $2.25 | **$2.50 - $2.65** | • Strong double-digit growth, >10% YoY<br>• Excludes impact of future share repurchases |

# Appendix

# ENHANZE® Partner Product Development Pipeline

## Wave 3 Pipeline

| Current Program/Product | Indications | Phase 1 | Phase 2 | Phase 3 | Filed |
|---|---|---|---|---|---|
| **Wave 3** | | | | | |
| **Efgartigimod (argenx)** | MG | | | | |
| **Atezolizumab (Roche)** | NSCLC | | | | |
| **Ocrelizumab (Roche)** | Multiple sclerosis | | | | |
| **Nivolumab (BMS)** | RCC | | | | |
| **Nivolumab (BMS)** | Melanoma | | | | |
| **Efgartigimod (argenx)** | CIDP | | | | |
| **Efgartigimod (argenx)** | Immune thrombocytopenia | | | | |
| **Efgartigimod (argenx)** | Pemphigus | | | | |
| **Efgartigimod (argenx)** | Bullous Pemphigoid (BP) | | | | |
| **Efgartigimod (argenx)** | Myositis | | | | |

# ENHANZE® Partner Product Development Pipeline

## Wave 4 Pipeline

| Current Program/Product | Indications | Phase 1 | Phase 2 | Phase 3 | Filed |
|---|---|---|---|---|---|
| **Wave 4** | | | | | |
| **Amivantamab (Janssen)** | Solid malignancies | | | | |
| **Nivolumab+Relatlimab (BMS)** | Solid tumors | | | | Phase 3 to start soon |
| **ARGX-117 (argenx)** | Multifocal motor neuropathy | | | | |
| **Teprotumumab-trbw (Horizon)** | Thyroid Eye Disease | | | | |
| **Rilpivirine (Janssen)** | HIV | | | | |
| **Undisclosed (Roche)** | Undisclosed | | | | |
| **TAK-881 (Takeda)** | Immune | | | | |
| **Cabotegravir (ViiV)** | HIV | | | | |
| **N6LS bnAb (ViiV)** | HIV (treatment) | | | | |
| **Undisclosed (Chugai)** | Undisclosed | | | | |